# Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS

> **NCT03918304** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 923 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03918304
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-11
- **Primary completion:** 2024-10-27
- **Final completion:** 2024-10-27
- **Target enrollment:** 923 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03918304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03918304, "Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03918304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*